Brian E Lacy

List of Publications by Citations

Source: https://exaly.com/author-pdf/3725802/brian-e-lacy-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

105 6,022 33 77 g-index

120 7,775 3.6 ext. papers ext. citations avg, IF 6.44 L-index

#	Paper	IF	Citations
105	Bowel Disorders. <i>Gastroenterology</i> , 2016 ,	13.3	1260
104	Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1547-61; quiz 1546, 1562	0.7	447
103	American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. <i>American Journal of Gastroenterology</i> , 2014 , 109 Suppl 1, S2-26; quiz S27	0.7	393
102	Irritable Bowel Syndrome. New England Journal of Medicine, 2017, 376, 2566-2578	59.2	291
101	Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1350-65; quiz 1366	0.7	262
100	ACG and CAG Clinical Guideline: Management of Dyspepsia. <i>American Journal of Gastroenterology</i> , 2017 , 112, 988-1013	0.7	259
99	Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1044-1060	6.1	248
98	The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1367-74	0.7	202
97	Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study. <i>Gastroenterology</i> , 2015 , 149, 340-9.e2	13.3	198
96	Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2019 , 114, 21-39	0.7	185
95	A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1290-1300	0.7	173
94	Opioid-Induced Esophageal Dysfunction (OIED) in Patients on Chronic Opioids. <i>American Journal of Gastroenterology</i> , 2015 , 110, 979-84	0.7	125
93	Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients. <i>Gastroenterology</i> , 2016 , 150, 911-7; quiz e19	13.3	118
92	ACG Clinical Guideline: Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021 , 116, 17-44	0.7	98
91	Mechanisms, Evaluation, and Management of Chronic Constipation. <i>Gastroenterology</i> , 2020 , 158, 1232-	12 <u>4</u> 9.e	391
90	The diagnosis of gastroesophageal reflux disease. American Journal of Medicine, 2010, 123, 583-92	2.4	84
89	Lubiprostone: a chloride channel activator. <i>Journal of Clinical Gastroenterology</i> , 2007 , 41, 345-51	3	73

(2019-2018)

88	Physician Burnout: The Hidden Health Care Crisis. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 311-317	6.9	68	
87	Gastroparesis: Quality of Life and Health Care Utilization. <i>Journal of Clinical Gastroenterology</i> , 2018 , 52, 20-24	3	53	
86	Safety and tolerability of transoral Bravo capsule placement after transnasal manometry using a validated conversion factor. <i>American Journal of Gastroenterology</i> , 2007 , 102, 24-32	0.7	53	
85	Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. <i>American Journal of Gastroenterology</i> , 2017 , 112, 365-374	0.7	52	
84	Functional dyspepsia is associated with sleep disorders. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 410-4	6.9	52	
83	Management options for patients with GERD and persistent symptoms on proton pump inhibitors: recommendations from an expert panel. <i>American Journal of Gastroenterology</i> , 2018 , 113, 980-986	0.7	50	
82	Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial. <i>PLoS ONE</i> , 2015 , 10, e0134349	3.7	50	
81	Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials. <i>American Journal of Gastroenterology</i> , 2019 , 114, 233-243	0.7	46	
80	The treatment of irritable bowel syndrome. <i>Therapeutic Advances in Gastroenterology</i> , 2009 , 2, 221-38	4.7	45	
79	Anatomy and Physiology of the Small Bowel. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2017 , 27, 1-13	3.3	41	
78	Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 143-52	4	41	
77	PhysiciansRattitudes and practices in the evaluation and treatment of irritable bowel syndrome. <i>Scandinavian Journal of Gastroenterology</i> , 2006 , 41, 892-902	2.4	41	
76	Functional dyspepsia and gastroparesis: one disease or two?. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1615-20	0.7	39	
75	A prospective study to compare a symptom-based reflux disease questionnaire to 48-h wireless pH monitoring for the identification of gastroesophageal reflux (revised 2-26-11). <i>American Journal of Gastroenterology</i> , 2011 , 106, 1604-11	0.7	39	
74	Gastrointestinal motility disorders: an update. <i>Digestive Diseases</i> , 2006 , 24, 228-42	3.2	35	
73	Low-Dose Linaclotide (72 년) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. <i>American Journal of Gastroenterology</i> , 2018 , 113, 105-114	0.7	33	
72	Esophageal motility disorders: medical therapy. <i>Journal of Clinical Gastroenterology</i> , 2008 , 42, 652-8	3	32	
71	Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819878950	o 4·7	30	

70	Gastroparesis: Medical and Therapeutic Advances. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 2231-2240	4	30
69	Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use. <i>American Journal of Gastroenterology</i> , 2017 , 112, 924-932	0.7	29
68	Chronic nausea and vomiting: evaluation and treatment. <i>American Journal of Gastroenterology</i> , 2018 , 113, 647-659	0.7	29
67	Chronic constipation: new diagnostic and treatment approaches. <i>Therapeutic Advances in Gastroenterology</i> , 2012 , 5, 233-47	4.7	28
66	Gastric motility, gastroparesis, and gastric stimulation. <i>Surgical Clinics of North America</i> , 2005 , 85, 967-87, vi-vii	4	28
65	The Science, Evidence, and Practice of Dietary Interventions in Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1899-906	6.9	27
64	Gastrointestinal Manifestations of Rheumatological Diseases. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1441-1454	0.7	26
63	Opioid-Induced Esophageal Dysfunction: Differential Effects of Type and Dose. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1464-1469	0.7	26
62	Irritable bowel syndrome: a syndrome in evolution. Journal of Clinical Gastroenterology, 2005, 39, S230-	43	25
61	Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations. <i>Journal of the American Association of Nurse Practitioners</i> , 2016 , 28, 393-404	1	23
60	Identification of Quality Measures for Performance of Indunterpretation of Data From Esophageal Manometry. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 526-534.e1	6.9	22
59	A 32-year-old woman with chronic abdominal pain. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 555-65	27.4	20
58	Variation in Care for Patients with Irritable Bowel Syndrome in the United States. <i>PLoS ONE</i> , 2016 , 11, e0154258	3.7	20
57	Management of Chronic Abdominal Distension and Bloating. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 219-231.e1	6.9	20
56	IBS patientsRwillingness to take risks with medications. <i>American Journal of Gastroenterology</i> , 2012 , 107, 804-9	0.7	18
55	Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 817-830	6.1	17
54	Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756284818771674	4.7	16
53	The effects of nebulized albuterol on esophageal function in asthmatic patients. <i>Digestive Diseases and Sciences</i> , 2008 , 53, 2627-33	4	15

52	A System to Assess the Competency for Interpretation of Esophageal Manometry Identifies Variation in Learning Curves. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1708-1714.e3	6.9	14
51	Dietary Interventions and Irritable Bowel Syndrome: A Review of the Evidence. <i>Current Gastroenterology Reports</i> , 2016 , 18, 41	5	13
50	Functional Dyspepsia: Clinical Symptoms, Psychological Findings, and GCSI Scores. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 1281-1287	4	13
49	Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 311-22	4	12
48	Common anorectal disorders: diagnosis and treatment. Current Gastroenterology Reports, 2009, 11, 413	- 9 j	12
47	The clinical utility of esophageal manometry. <i>Journal of Clinical Gastroenterology</i> , 2009 , 43, 809-15	3	12
46	The Proton Pump Inhibitor Non-Responder: A Clinical Conundrum. <i>Clinical and Translational Gastroenterology</i> , 2015 , 6, e106	4.2	11
45	On-demand hyoscine butylbromide for the treatment of self-reported functional cramping abdominal pain. <i>Scandinavian Journal of Gastroenterology</i> , 2013 , 48, 926-35	2.4	11
44	Functional dyspepsia: time to change clinical trial design?. <i>American Journal of Gastroenterology</i> , 2010 , 105, 2525-9	0.7	11
43	A Novel, Duodenal-Release Formulation of a Combination of Caraway Oil and L-Menthol for the Treatment of Functional Dyspepsia: A Randomized Controlled Trial. <i>Clinical and Translational Gastroenterology</i> , 2019 , 10, e00021	4.2	11
42	Development of a Symptom-Focused Patient-Reported Outcome Measure for Functional Dyspepsia: The Functional Dyspepsia Symptom Diary (FDSD). <i>American Journal of Gastroenterology</i> , 2018 , 113, 39-48	0.7	10
41	Postobesity Surgery Esophageal Dysfunction: A Combined Cross-Sectional Prevalence Study and Retrospective Analysis. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1669-1680	0.7	10
40	Polymorphisms of 5-HTT LPR and GNB 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial. <i>American Journal of Gastroenterology</i> , 2017 , 112, 903-909	0.7	9
39	Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 175628481984	1 2 90	9
38	Medication risk-taking behavior in functional dyspepsia patients. <i>Clinical and Translational Gastroenterology</i> , 2015 , 6, e69	4.2	9
37	Tolerability and clinical utility of the Bravo pH capsule in children. <i>Journal of Clinical Gastroenterology</i> , 2009 , 43, 514-9	3	9
36	Symptomatic Management of Gastroparesis. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2019 , 29, 55-70	3.3	9
35	Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284818818326	4.7	9

34	Quality of Care and the Irritable Bowel Syndrome: Is Now the Time to Set Standards?. <i>American Journal of Gastroenterology</i> , 2018 , 113, 167-169	0.7	9
33	The willingness of patients with gastroparesis to take risks with medications. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 429-436	6.1	8
32	Prucalopride for chronic constipation. <i>Drugs of Today</i> , 2009 , 45, 843-53	2.5	7
31	Update on the Management of Chronic Constipation. <i>Current Treatment Options in Gastroenterology</i> , 2017 , 15, 126-134	2.5	6
30	Clinical utility of the wireless pH capsule. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 429-35	3	6
29	Diagnosing Small Intestinal Bacterial Overgrowth: A Comparison of Lactulose Breath Tests to Small Bowel Aspirates. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 2042-2050	4	6
28	Neuroenteric Stimulation for Gastroparesis. <i>Current Treatment Options in Gastroenterology</i> , 2015 , 13, 409-17	2.5	5
27	Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1601-1611	0.7	5
26	Patients With Irritable Bowel Syndrome Are Willing to Take Substantial Medication Risks for Symptom Relief. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 80-86	6.9	5
25	Gastric Emptying Scans: Poor Adherence to National Guidelines. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 2897-2906	4	4
24	Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1587-1600	0.7	4
23	Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 98-10	8 ^{6.1}	4
22	Partnering with gastroenterologists to evaluate patients with chronic constipation. <i>MedGenMed: Medscape General Medicine</i> , 2005 , 7, 19		3
21	Introduction to the 80% by 2018 Special Issue. American Journal of Gastroenterology, 2018, 113, 1737-17	738 ₇	3
20	Recent advances in the management of difficult constipation. <i>Current Gastroenterology Reports</i> , 2012 , 14, 306-12	5	2
19	Negative Is Positive. American Journal of Gastroenterology, 2016 , 111, 1505	0.7	2
18	Lessons learned: Chronic idiopathic constipation patient experiences with over-the-counter medications. <i>PLoS ONE</i> , 2021 , 16, e0243318	3.7	2
17	Diagnostic Evaluation of Gastric Motor and Sensory Disorders <i>American Journal of Gastroenterology</i> , 2021 , 116, 2345-2356	0.7	2

LIST OF PUBLICATIONS

16	Response to Croteau and Barkin. American Journal of Gastroenterology, 2017, 112, 1617	0.7	1
15	Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. AuthorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1254-1255	6.1	1
14	Clinical pearls for irritable bowel syndrome: management of the diarrhea-predominant subtype. <i>Gastroenterology Nursing</i> , 2014 , 37, 392-405	1	1
13	Management of irritable bowel syndrome with diarrhea: focus on eluxadoline. <i>Current Medical Research and Opinion</i> , 2021 , 37, 567-578	2.5	1
12	Controversies in Gastroparesis: Discussing the Sticky Points. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1572-1576	0.7	1
11	Putting Patients First. American Journal of Gastroenterology, 2018, 113, 1	0.7	1
10	Hot Topics in Primary Care: Role of the Microbiome in Disease: Implications for Treatment of Irritable Bowel Syndrome. <i>Journal of Family Practice</i> , 2017 , 66, S40-S45	0.2	1
9	A novel duodenal-release formulation of caraway oil and L-menthol is a safe, effective and well tolerated therapy for functional dyspepsia <i>BMC Gastroenterology</i> , 2022 , 22, 105	3	1
8	The American Journal of Gastroenterology in 2016: Where Have We Been? Where Are We Going?. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1-3	0.7	O
7	Lymphocytic Esophagitis: Assessing Risk Factors and Clinical Outcomes. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 3976-3984	4	O
6	Post-marketing reports of pancreatitis in eluxadoline-treated patients pre and post US label change. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211001725	4.7	O
5	Response to Marlicz et al. <i>American Journal of Gastroenterology</i> , 2018 , 113, 781	0.7	
4	How effective is tegaserod for the treatment of female patients with mixed subtype IBS?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008 , 5, 664-5		
3	70-Year-Old Man With Chronic Nausea and Vomiting. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 3142-3146	6.4	
2	Extent of eosinophilic esophagitis predicts response to treatment. <i>Endoscopy International Open</i> , 2021 , 9, E1234-E1242	3	
1	A Practical Approach to the Diagnosis and Treatment of Abdominal Bloating and Distension <i>Gastroenterology and Hepatology</i> , 2022 , 18, 75-84	0.7	